VanEck Pharmaceutical ETF
PPH
59 hedge funds and large institutions have $225M invested in VanEck Pharmaceutical ETF in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 7 closing their positions.
43% more capital invested
Capital invested by funds: $157M → $225M (+$68.1M)
20.11% more ownership
Funds ownership: 49.03% → 69.14% (+20%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 60 → 59 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
26% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$23.2M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.78M |
| 3 |
LPL Financial
San Diego,
California
|
+$927K |
| 4 |
M&T Bank
Buffalo,
New York
|
+$875K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$537K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.59M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$4.68M |
| 3 |
MIM
Macroview Investment Management
Bethesda,
Maryland
|
-$2.84M |
| 4 |
Jane Street
New York
|
-$2.45M |
| 5 |
VF
Virtu Financial
New York
|
-$2.21M |
PPH Hedge Fund Activity: Q4 2015 in Review
59 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2015, worth a combined $225M — up 43% from $157M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PPH and 6 opened new positions — a net loss of 1 holder — while 19 trimmed existing stakes and 14 added.
The largest buyer was Goldman Sachs, adding an estimated $23.2M. The largest seller was Morgan Stanley, cutting an estimated $5.59M.
- 59 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2015, down from 60 in Q3 2015.
- Funds reported $225M of VanEck Pharmaceutical ETF stock for Q4 2015, up 43% quarter-over-quarter.
- 6 funds opened new VanEck Pharmaceutical ETF positions in Q4 2015 and 7 closed out, a net change of -1 holder.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2015 was Goldman Sachs, an estimated $23.2M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2015 was Morgan Stanley, an estimated $5.59M sold.
Based on aggregated 13F filings for Q4 2015.